Sutro Biopharma Inc (STRO)
Sutro Biopharma is a clinical-stage oncology company developing site-specific and antibody drug conjugates (ADCs) enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF®, and its site-specific conjugation platform, XpressCF+®. Co.'s product candidate is STRO-002, or luveltamab tazevibulin, an ADC directed against folate receptor-alpha (FolRa) for patients with FolRa-expressing cancers, including ovarian cancer. Co.'s other product candidate is STRO-001, an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma. Co. also has a preclinical product candidate, STRO-003, which is a single homogeneous ADC.
STRO SEC Filing Email Alerts Service
| Company Name: |
Sutro Biopharma Inc |
| Website: |
www.sutrobio.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding STRO: |
16 |
| Total Market Value Held by ETFs: |
$17.90M |
| Total Market Capitalization: |
$220.00M |
| % of Market Cap. Held by ETFs: |
8.14% |
|
|
May 2, 2024 • 5:08 AM Eastern
Strong Buy (3.80 out of 4)
71st percentile
|
|
Free STRO Email Alerts:
